Micro Labs Launches Linapride DM: Affordable Diabetes Treatment in India

Uncontrolled Diabetes has become a major challenge in today's Diabetes Management and it keeps raising the bar. As per the ICMR-INDIAB Study published in Lancet Diabetes Endocrinology 2022, The target HbA1c i.e 7% is achieved only by 36.3% of Diabetes Patients in India. This prompts the dire need for early aggressive combination therapy.

Micro Labs, launches Linapride DM for diabetes patients in India. This medication targets uncontrolled T2DM patients on dual therapy, with or without high-risk comorbid conditions such as cardiovascular disease (CVD), obesity, and chronic kidney disease (CKD).

Approved by DCGI for T2DM management, Linapride DM comes in two dosage strengths: Linapride DM 500 and Linapride DM 1000. Recognizing the economic burden of diabetes Micro Labs is launching Linapride DM at an affordable price, Linapride DM 500 is available at Rs.168 per Strip of 10 tablets while Linapride DM 1000 is available at Rs.178 per Strip of 10 tablets, ensuring all patients have access to essential treatment.

Linapride DM's combination Scores 8 on 8 in the ominous octet of type 2 diabetes.

Speaking to Medical Dialogues, B R Srinath, Sr. Vice President of Sales and Marketing, Micro labs said, "With over 10 crore individuals affected by diabetes in India, patients with T2DM often face comorbidities that complicate disease management. Many of these patients require multiple medications to control hyperglycemia, hypertension, and other conditions".

G Seshagiri, Vice President of Marketing & Sales, Micro labs also added, "Despite advancements in diabetes care, many T2DM patients struggle to reach their blood sugar goals due to concerns about hypoglycemia & weight gain. Keeping in mind the long-term therapy in diabetes care, Linapride DM offers significant savings to the patients & above all ensures Compliance".